News stories about Celgene (NASDAQ:CELG) have trended somewhat positive on Monday, Accern reports. The research firm scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Celgene earned a daily sentiment score of 0.04 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 44.2821271200315 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:
- SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have … (globenewswire.com)
- SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Celgene Corporation (Nasdaq: CELG) To Contact Brower Piven Before The Lead Plaintiff Deadline (finance.yahoo.com)
- CELGENE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC … (globenewswire.com)
- CELGENE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Celgene Corporation – CELG (finance.yahoo.com)
- Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Celgene Corporation (CELG) and Encourages Investors to Contact the Firm (markets.financialcontent.com)
CELG has been the subject of several analyst reports. Mizuho reissued a “buy” rating and issued a $128.00 price objective on shares of Celgene in a research note on Sunday, February 4th. Credit Suisse Group set a $125.00 price objective on Celgene and gave the stock a “buy” rating in a research note on Monday, January 8th. Cann reissued a “buy” rating and issued a $163.00 price objective on shares of Celgene in a research note on Thursday, February 15th. Goldman Sachs lowered their price objective on Celgene from $97.00 to $85.00 and set a “sell” rating for the company in a research note on Monday, March 26th. Finally, Vetr downgraded Celgene from a “strong-buy” rating to a “buy” rating and set a $121.72 price objective for the company. in a research note on Monday, December 18th. Three analysts have rated the stock with a sell rating, twelve have assigned a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $127.68.
NASDAQ CELG traded down $2.14 on Monday, hitting $87.07. 6,879,755 shares of the stock traded hands, compared to its average volume of 8,098,341. Celgene has a 12 month low of $84.95 and a 12 month high of $147.17. The firm has a market cap of $67,101.59, a price-to-earnings ratio of 12.73, a price-to-earnings-growth ratio of 0.60 and a beta of 1.48. The company has a current ratio of 4.99, a quick ratio of 4.80 and a debt-to-equity ratio of 2.29.
Celgene (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, January 25th. The biopharmaceutical company reported $1.87 earnings per share for the quarter, beating the consensus estimate of $1.78 by $0.09. Celgene had a return on equity of 67.50% and a net margin of 22.38%. The business had revenue of $3.48 billion during the quarter, compared to analyst estimates of $3.46 billion. During the same period in the prior year, the company earned $1.61 earnings per share. Celgene’s revenue was up 16.9% compared to the same quarter last year. analysts forecast that Celgene will post 7.66 EPS for the current year.
Celgene declared that its board has approved a share buyback program on Wednesday, February 14th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the biopharmaceutical company to repurchase shares of its stock through open market purchases. Shares repurchase programs are usually a sign that the company’s board of directors believes its shares are undervalued.
In other news, Director James J. Loughlin sold 9,250 shares of the firm’s stock in a transaction on Monday, March 12th. The stock was sold at an average price of $92.01, for a total value of $851,092.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ernest Mario sold 13,370 shares of the firm’s stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $94.49, for a total value of $1,263,331.30. The disclosure for this sale can be found here. Insiders sold 41,120 shares of company stock valued at $3,879,509 over the last ninety days. Corporate insiders own 0.95% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Celgene (CELG) Earning Somewhat Favorable Media Coverage, Report Shows” was originally published by Enterprise Leader and is the property of of Enterprise Leader. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://theenterpriseleader.com/2018/04/02/celgene-celg-earning-somewhat-favorable-media-coverage-report-shows.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.